Pseudomonas aeruginosa elastase (LasB) as a therapeutic target

Drug Discov Today. 2021 Sep;26(9):2108-2123. doi: 10.1016/j.drudis.2021.02.026. Epub 2021 Mar 3.

Abstract

Why is P. aeruginosa LasB elastase an attractive target for antivirulence therapy and what is the state-of-the art in LasB inhibitor design and development?

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Proteins / antagonists & inhibitors*
  • Bacterial Proteins / metabolism
  • Drug Development
  • Humans
  • Metalloendopeptidases / antagonists & inhibitors*
  • Metalloendopeptidases / metabolism
  • Pancreatic Elastase / antagonists & inhibitors*
  • Pancreatic Elastase / metabolism
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / enzymology
  • Pseudomonas aeruginosa / pathogenicity
  • Virulence

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Pancreatic Elastase
  • Metalloendopeptidases
  • pseudolysin, Pseudomonas aeruginosa